Avalyn Pharma - About the company
Avalyn Pharma is a public company based in Seattle (United States), founded in 2011 by Richard G. Vincent and Mark Surber. It operates as a Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis. Avalyn Pharma has raised $389M in funding from investors like SR One, Norwest and Edmond de Rothschild. The company has 2069 active competitors, including 465 funded and 330 that have exited. Its top competitors include companies like Antheia, Transcenta and Akeso.
Company Details
Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis. The company's lead program, Aerodone inhaled pirfenidone provides GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. FDA has granted orphan-drug designation to Genoa for the use of pirfenidone.
- Website
- www.avalynpharma.com/
- Email ID
- *****@avalynpharma.com
- Phone Number
- +1 **********
- Registered Address
- 1999 BRYAN ST STE 900,DALLAS,TX,75201.0,57
Key Metrics
Founded Year
2011
Location
Seattle, United States
Stage
Public
Total Funding
$389M in 6 rounds
Latest Funding Round
Ranked
12th among 2069 active competitors
Employee Count
68 as on Sep 30, 2026
Exit Details
Public
Legal entities associated with Avalyn Pharma
Avalyn Pharma is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Avalyn Pharma Inc. CIN: 32094123372 , United States, Active | Mar 09, 2024 | - | - | - |
Avalyn Pharma's IPO details
Avalyn Pharma got listed on Apr 30, 2026.
Click here to take a look at Avalyn Pharma's IPO in detail
Sign up to download Avalyn Pharma's company profile
Avalyn Pharma's funding and investors
Avalyn Pharma has raised a total funding of $389M over 6 rounds. Its first funding round was on Aug 11, 2015. Its latest funding round was a Series D round on Jul 22, 2025 for $*****. 4 investors participated in its latest round. Avalyn Pharma has 24 institutional investors.
Here is the list of recent funding rounds of Avalyn Pharma:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 22, 2025 | 6498874 | Series D | 5582541 | 7005909 | 3704990 | 4161144 |
Sep 27, 2023 | 4727364 | Series C | 9720149 | 6200237 | 2664064 | |
Apr 27, 2020 | 8003244 | Series B | 4846850 | 7805974 |
Access funding benchmarks and valuations. Sign up today!View details of Avalyn Pharma's funding rounds and investors
Avalyn Pharma's founders and board of directors
Founder? Claim ProfileThe founders of Avalyn Pharma are Richard G. Vincent and Mark Surber.
Here are the details of Avalyn Pharma's key team members:
- Richard G. Vincent: Co-Founder & CFO of Avalyn Pharma and founder of 1 other company.
- Mark Surber: Founder of Avalyn Pharma. Contact Info: 1 email address
View details of Avalyn Pharma's Founder profiles and Board Members
Avalyn Pharma's employee count trend
Avalyn Pharma has 68 employees as of Sep 26. Here is Avalyn Pharma's employee count trend over the years:
Uncover Avalyn Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Avalyn Pharma's Competitors and alternates
Top competitors of Avalyn Pharma include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of Avalyn Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $176M | 67/100 | |
2nd | Transcenta 2019, Suzhou (China), Public | Developer of antibody-based therapeutics | $205M | 66/100 | |
3rd | Developer of antibody drug conjugates for the treatment of broad spectrum diseases | $195M | 65/100 | ||
4th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases | $4M | 64/100 | |
5th | Novogene Corporation 2011, Beijing (China), Series B | Provider of genomic services and solutions | $75M | 64/100 | |
6th | Fermentalg 2005, Libourne (France), Public | Innovating with algae for sustainable solutions in nutrition and environmental impact | $30.3M | 63/100 | |
7th | Microban 1994, Huntersville (United States), Acquired | Antimicrobial and odor control technologies for durable product protection and freshness | $64.6M | 63/100 | |
8th | Skyhawk Therapeutics 2017, Waltham (United States), Series B | Developer of RNA-modifying drug candidates for the treatment of multiple disorders | $181M | 63/100 | |
9th | LifeMine Therapeutics 2016, Watertown (United States), Series E | Developer of novel drugs from fungi via genome mining and recombinant overexpression | $563M | 63/100 | |
10th | One Biosciences 2020, Paris (France), Series A | Developer of single-cell therapeutics solutions to treat multiple health disorders | $22.4M | 62/100 | |
12th | Avalyn Pharma 2011, Seattle (United States), Public | Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis | $389M | 63/100 |
_1523881431192.png?devicePixelRatio=2&height=30&width=30){kind=logo}
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Avalyn Pharma's competitors? Click here to see the top ones
Avalyn Pharma's Investments and acquisitions
Avalyn Pharma has made no investments or acquisitions yet.
Reports related to Avalyn Pharma
Here is the latest report on Avalyn Pharma's sector:
News related to Avalyn Pharma
Filter this listMedia has covered Avalyn Pharma for a total of 12 events in the last 1 year, 5 of them have been about company updates and 1 about people movement.
•
Avalyn Pharma Publishes Phase 1 Data for AP02 Highlighting Lung-Targeted Delivery and SafetyGlobeNewswire•Sep 21, 2026•Avalyn Pharma
•
Avalyn Pharma Announces Presentations at European Respiratory Society International Congress 2026GlobeNewswire•Aug 25, 2026•Avalyn Pharma
•
Behind the bell: Avalyn Pharma and Generate Biomedicines discuss the rewarding moments of taking their companies publicBioSpace•Aug 13, 2026•Avalyn Pharma, Generate Biomedicines
•
Avalyn Pharma Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire•Aug 12, 2026•Avalyn Pharma
•
Avalyn Pharma (NASDAQ:AVLN) Shares Down 8.9% – Should You Sell?Thecerbatgem•Jul 01, 2026•Avalyn Pharma
•
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 for Progressive Pulmonary FibrosisGlobeNewswire•Jun 17, 2026•Avalyn Pharma
•
Avalyn Pharma Reports First Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire•Jun 03, 2026•Avalyn Pharma
•
Avalyn Pharma Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SGlobeNewswire•May 01, 2026•Avalyn Pharma
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Avalyn Pharma
Explore our recently published companies
- Ella Bella - Unfunded company
- Smart Fix - Unfunded company
- Jmb Jewels - Bengaluru based, 2011 founded, Unfunded company
- Unistar Special Risks - Calgary based, 2000 founded, Unfunded company
- Nutritionpartners - 2003 founded, Unfunded company
- Pacific Home - Saskatoon based, 1986 founded, Unfunded company
